AXDX vs. INTT, ODYS, AKYA, MASS, OWLT, PRE, OPTX, OMIC, AATC, and MSAI
Should you be buying Accelerate Diagnostics stock or one of its competitors? The main competitors of Accelerate Diagnostics include inTEST (INTT), Odysight.Ai (ODYS), Akoya Biosciences (AKYA), 908 Devices (MASS), Owlet (OWLT), Prenetics Global (PRE), Syntec Optics (OPTX), Singular Genomics Systems (OMIC), Autoscope Technologies (AATC), and MultiSensor AI (MSAI). These companies are all part of the "measuring and control equipment" industry.
Accelerate Diagnostics vs.
inTEST (NYSE:INTT) and Accelerate Diagnostics (NASDAQ:AXDX) are both small-cap computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, community ranking, analyst recommendations, dividends, earnings, media sentiment and risk.
inTEST has higher revenue and earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than inTEST, indicating that it is currently the more affordable of the two stocks.
inTEST has a net margin of 2.33% compared to Accelerate Diagnostics' net margin of -471.83%. inTEST's return on equity of 5.31% beat Accelerate Diagnostics' return on equity.
inTEST presently has a consensus price target of $16.00, indicating a potential upside of 96.32%. Accelerate Diagnostics has a consensus price target of $1.00, indicating a potential downside of 3.85%. Given inTEST's stronger consensus rating and higher possible upside, equities analysts plainly believe inTEST is more favorable than Accelerate Diagnostics.
63.2% of inTEST shares are owned by institutional investors. Comparatively, 17.1% of Accelerate Diagnostics shares are owned by institutional investors. 5.5% of inTEST shares are owned by insiders. Comparatively, 43.6% of Accelerate Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
inTEST has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500. Comparatively, Accelerate Diagnostics has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500.
Accelerate Diagnostics received 344 more outperform votes than inTEST when rated by MarketBeat users. Likewise, 59.46% of users gave Accelerate Diagnostics an outperform vote while only 57.89% of users gave inTEST an outperform vote.
In the previous week, Accelerate Diagnostics had 3 more articles in the media than inTEST. MarketBeat recorded 3 mentions for Accelerate Diagnostics and 0 mentions for inTEST. Accelerate Diagnostics' average media sentiment score of 0.30 beat inTEST's score of 0.00 indicating that Accelerate Diagnostics is being referred to more favorably in the news media.
Summary
inTEST beats Accelerate Diagnostics on 12 of the 18 factors compared between the two stocks.
Get Accelerate Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Accelerate Diagnostics Competitors List
Related Companies and Tools
This page (NASDAQ:AXDX) was last updated on 3/3/2025 by MarketBeat.com Staff
